Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Citius Pharmaceuticals, Inc. - Common Stock (NQ:CTXR)

1.020 -0.160 (-13.56%)
Streaming Delayed Price Updated: 3:21 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Citius Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
11 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Rubius Therapeutics (NASDAQ:RUBY) shares moved upwards by 30.46% to $0.59. The market value of their outstanding shares is at $53.5 million. 
Via Benzinga
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
Via Benzinga
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
Gainers 
Via Benzinga
Citius Pharma To Spinoff Late-Stage Oncology Asset Into New Publicly Traded Firm
Via Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Spearheads the Global Cancer Immunotherapy Market
Via Get News
Exposures Product Safety
Citius Pharma Reveals Topline Immunotherapy Data From Late-Stage Lymphoma Trial
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers that traders need to watch! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is Specializing in Stem Cell Therapy & Critical Cancer Care Immunotherapy
Via Get News
Exposures Product Safety
3 Reddit Stocks to Buy in May
These trending Reddit stocks have considerable growth catalysts in motion, offering healthy upside potential in May and beyond 
Via InvestorPlace
Citius Pharmaceuticals, Inc is helping Global Cancer Immunotherapy to reach the Market Cap of 152 Billion by 2024.
Via AB Newswire
Exposures Product Safety
The Global Cancer immunotherapy market is expected to reach 152 Billion by 2024 led by Astra Zeneca Nasdaq: AZN; Celgene Corp. (NASDAQ: CELG) Including Late Stage Newcomer; Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)
Via Viz Release
Exposures COVID-19 Product Safety
First Patient Dosed in Citius Pharma's Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced enrolment of first patient in the Phase 2b clinical study of Halo-Lido for the treatment of hemorrhoids. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Healthcare Triangle (NASDAQ:HCTI) stock moved upwards by 17.5% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $47.6... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 16.4% to $7.72 during Thursday's regular session. The current volume of 639.5K shares is 152.7% of... 
Via Benzinga
Penny Stock Watchlist - Here Are My Five Top Picks
If you got into Amazon at the start of 2021, by the end of 2021 you'd have made about 73% gains. Not bad for a year. It's impressive until you consider that one of these stocks made 258% gains in the... 
Via Talk Markets
FDA Signs Off Citius Pharma's Phase 2 Trial With Halo-Lido In Hemorrhoids
The FDA has issued a Study May Proceed letter for Citius Pharmaceuticals Inc's (NASDAQ: CTXR) Halo-Lido to treat hemorrhoids. The Company anticipates... 
Via Benzinga
Citius Pharmaceuticals: Q1 Earnings Insights
Citius Pharmaceuticals (NASDAQ:CTXR) reported its Q1 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Citius... 
Via Benzinga
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2021
Upgrades Sidoti & Co. upgraded the previous rating for DMC Global Inc (NASDAQ: 
Via Benzinga
Citius Pharmaceuticals Addresses Unmet Needs for Patients with CVCs
Image by falco from Pixabay What happens when the one product keeping you alive becomes infected? Central venous catheters (CVCs) are important life lines for treating many... 
Via Benzinga
Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?
A lot would have to go right for this biotech to make investors rich. 
Via The Motley Fool
56 Biggest Movers From Friday
Gainers Sequential Brands Group, Inc. (NASDAQ: SQBG) jumped 89.2% to settle at $15.70. Eco Wave Power Global AB (NASDAQ: WAVE) shares surged 73.2% to close at $18.79. A 13G... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5... 
Via Benzinga
24 Stocks Moving in Friday's Pre-Market Session
Gainers T.A.T. Technologies Ltd. (NASDAQ: TATT) shares rose 53.4% to $9.09 in pre-market trading after the company announced a new MRO partnership with Honeywell. Staffing 360... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share. Pop Culture Group Co., Ltd (... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.